we now have 64 RFS events (83% of the expected information) and the qualitative results  Itraconazole remain the same: there is no clinically relevant difference between the two treatment arms in terms of RFS or pCR.patients with metastatic breast cancer started capecitabine at the registered dose and suggested that the efficacy of capecitabine seen in clinical trials could be reproduced in routine practice despite the widespread use of lower doses to improve tolerability. Finally, 6% of patients had HER2-positive breast cancer and did not receive trastuzumab because it was not the standard of care at the time of study initiation. Ongoing studies will provide further information on the value of capecitabine in the adjuvant setting, and exploratory analyses of existing studies will examine whether a differential benefit exists between breast cancer subtypes. In conclusion,XTcompared withWPdid not improve RFS and was associated with significantly more hematologic, skin, and mucosal toxicity.

Biliary tract cancers or cholangiocarcinomas are malignant tumors arising anywhere in the mucosa lining the biliary tract. Anatomically, they are divided into intrahepatic, perihilar, or  axitinib extrahepatic tumors and include Klatskin’s tumors and gall bladder cancer. The annual incidence is up to 1/100 000 in Western countries but much higher in other parts of the World. The only curative treatment is radical resection, but only a small fraction of the patients have resectable disease at presentation. Furthermore, most patients undergoing resection will eventually relapse. Thus, there is a need for systemic treatment. Regimens combining platinum and gemcitabine are considered as a standard chemotherapy in nonresectable patients. In Denmark, a combination of gemcitabine, oxaliplatin, and purchase risedronate capecitabine has been evaluated in phase I and phase II trials.

Based on experience with other gastrointestinal tumors, additional effect may be expected when combining chemotherapy and epidermal growth factor receptor (EGFR) antibodies.The literature on EGFR inhibition in biliary tract cancer is sparse. The EGFR is overexpressed in a fraction of biliary tract cancer and it may be targeted. There are order risedronate casuistic reports on the effect of the EGFR antibody cetuximab and in a small study by Paule et al. cetuximab reverted chemoresistance in two of nine patients. Besides cetuximab, one other EGFR antibody has been approved, panitumumab. Panitumumab is a fully humanized antibody targeting the extracellular domain of the EGFR. Specific antineoplastic effect in colorectal cancer seems to depend on normal function of the signaling protein KRAS in the EGFR pathway as responses are only seen in KRAS wild-type (wt) tumors and not in tumors with self-activating mutations. The purpose of this phase II trial was through a markerdriven approach to investigate the efficacy of combination chemotherapy and the EGFR inhibitor panitumumab in KRAS wild-type biliary tract cancer.

Eligible patients were at least 18 years of age with a performance status of zero to two and irresectable biliary tract cancer defined as either histologically definitive diagnosis or epithelial tissue  malignant cells consistent with biliary tract cancer and simultaneous radiologically evident findings without curative options.